Do Patients with Alcohol Dependence Respond to Placebo? Results from the COMBINE Study
Overview
Affiliations
Objective: The purpose of this study was to examine the nature of the effect of placebo medication plus accompanying medical management in the treatment of alcohol dependence.
Method: The National Institute on Alcohol Abuse and Alcoholism COMBINE (Combining Medications and Behavioral Interventions) study, a randomized controlled double-blind trial of 1,383 alcohol-dependent patients, compared combinations of medications (acamprosate [Campral] and naltrexone [ReVia]) and behavioral therapy (medical management and specialist-delivered behavioral therapy) for alcohol dependence. This report focuses on a subset of that study population (n = 466) receiving (1) specialized behavioral therapy alone (without pills), (2) specialized behavioral therapy + placebo medication + medical management, or (3) placebo + medical management.
Results: During 16 weeks of treatment, participants receiving behavioral therapy alone had a lower percentage of days abstinent (66.6%) than did the participants receiving placebo and medical management (73.1%) or those receiving specialized behavioral therapy + placebo + medical management (79.4%). The group receiving behavioral therapy alone relapsed to heavy drinking more often (79.0%) than those receiving behavioral therapy + placebo + medical management (71.2%). This report focuses on potential explanations for this finding. The two groups of participants receiving placebo + medical management were more likely to attend Alcoholics Anonymous meetings during treatment (32.7% and 32.0% vs 20.4%) and were less likely to withdraw from treatment (14.1% and 22.9% vs 29.3%).
Conclusions: There appeared to be a significant "placebo effect" in the COMBINE Study, consisting of pill taking and seeing a health care professional. Contributing factors to the placebo response may have included pill taking itself, the benefits of meeting with a medical professional, repeated advice to attend Alcoholics Anonymous, and optimism about a medication effect.
Editorial: Genome-wide molecular mechanisms of substance use disorders.
Blokhin I, Martinez-Garza D, Patel D, Douaihy A, Salloum I Front Psychiatry. 2024; 14:1356103.
PMID: 38260789 PMC: 10800646. DOI: 10.3389/fpsyt.2023.1356103.
Witkiewitz K, Garcia C, Muthen B Neurobiol Stress. 2024; 29:100602.
PMID: 38221942 PMC: 10784305. DOI: 10.1016/j.ynstr.2023.100602.
Wallach J, Glick L, Gueorguieva R, OMalley S Alcohol Clin Exp Res (Hoboken). 2023; 48(1):5-15.
PMID: 38102794 PMC: 10841726. DOI: 10.1111/acer.15229.
Duration of untreated illness in gambling disorder.
Grant J, Chamberlain S CNS Spectr. 2023; 29(1):54-59.
PMID: 37694344 PMC: 7615660. DOI: 10.1017/S1092852923002444.
Alcohol Use Disorder: Neurobiology and Therapeutics.
Yang W, Singla R, Maheshwari O, Fontaine C, Gil-Mohapel J Biomedicines. 2022; 10(5).
PMID: 35625928 PMC: 9139063. DOI: 10.3390/biomedicines10051192.